Sign In
Buy PPH
$103.47
+0.94 (+0.92%)
At Close: Jun 22, 2026
Vanguard (VHT) vs VanEck (PPH): Which Healthcare ETF Is the Better Buy?
06:21am, Thursday, 18'th Jun 2026
The Vanguard Health Care ETF offers a significantly lower expense ratio than the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF has a higher concentration and higher trailing returns, while
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
01:01pm, Wednesday, 10'th Jun 2026
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
07:20am, Friday, 05'th Jun 2026
Launched on December 20, 2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity mar
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns.
07:51am, Tuesday, 02'nd Jun 2026
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.
PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem
09:12am, Wednesday, 27'th May 2026
VanEck Pharmaceutical ETF offers a concentrated portfolio focused exclusively on drug manufacturers. iShares Global Healthcare ETF provides broader diversification across more than 100 companies in th
Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?
04:19pm, Tuesday, 19'th May 2026
The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
07:21am, Wednesday, 29'th Apr 2026
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund launched on June 23, 2005.
Could pressure to make money faster kill the next lifesaving pill?
11:27am, Wednesday, 15'th Apr 2026
When activist investors take a stake in a pharmaceutical company, markets often cheer. The expectation is leaner operations, sharper strategy and higher stock prices.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
07:22am, Thursday, 02'nd Apr 2026
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on Decemb
PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026
07:15am, Saturday, 28'th Mar 2026
VanEck Pharmaceutical ETF (NYSEARCA:PPH) exists to give investors broad exposure to the global pharmaceutical industry without the binary risk of betting on a single drug pipeline.
Avalon Trust Co Has $24.89 Million Position in VanEck Pharmaceutical ETF $PPH
04:06am, Monday, 23'rd Feb 2026
Avalon Trust Co lessened its holdings in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 1.8% during the undefined quarter, according to the company in its most recent disclosure with the SEC. Th
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
07:21am, Wednesday, 28'th Jan 2026
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on Decemb
VanEck Pharmaceutical ETF $PPH Shares Sold by Adamsbrown Wealth Consultants LLC
03:20am, Wednesday, 28'th Jan 2026
Adamsbrown Wealth Consultants LLC lowered its position in shares of VanEck Pharmaceutical ETF (NASDAQ: PPH) by 30.1% in the third quarter, according to its most recent 13F filing with the Securities a
VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion
10:36am, Friday, 23'rd Jan 2026
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund's concentrated bet on GLP-1 manufacturers makes this
